Results 51 to 60 of about 700,468 (343)

Blood-brain- barrier co-culture models to study nanoparticle penetration : focus on co-culture systems [PDF]

, 2015
The blood-brain barrier, as a physical, active transport and metabolic barrier represents the main obstacle in the treatment of central nervous system diseases.
Bocsik, Alexandra, Deli, Mária Anna, Hantosi, Dóra, Veszelka, Szilvia, Walter, Fruzsina R.   +4 more
core  

Bridging the gap: Multi‐stakeholder perspectives of molecular diagnostics in oncology

Molecular Oncology, EarlyView.
Although molecular diagnostics is transforming cancer care, implementing novel technologies remains challenging. This study identifies unmet needs and technology requirements through a two‐step stakeholder involvement. Liquid biopsies for monitoring applications and predictive biomarker testing emerge as key unmet needs. Technology requirements vary by
Jorine Arnouts, Senada Koljenović, Elise Daems, Karolien De Wael, Marc Peeters, Léon C. van Kempen, Greetje Vanhoutte, Karen Zwaenepoel, Timon Vandamme   +8 more
wiley   +1 more source

Investigation of Lysophospholipids-DHA transport across an in vitro human model of blood brain barrier

Heliyon
Several studies emphasized on the preventive and therapeutic potential of Docosahexaenoic Acid (DHA, 22:6n-3) supplementation in chronic and age-related disorders including neurodegenerative diseases.
Mayssa Hachem, Abdelmoneim H. Ali, Ibrahim Yildiz, Christophe Landry, Fabien Gosselet   +4 more
doaj   +1 more source

Recent Advances on Ultrasound Contrast Agents for Blood-Brain Barrier Opening with Focused Ultrasound

Pharmaceutics, 2020
The blood-brain barrier is the primary obstacle to efficient intracerebral drug delivery. Focused ultrasound, in conjunction with microbubbles, is a targeted and non-invasive way to disrupt the blood-brain barrier.
Ambre Dauba, Anthony Delalande, Hermes A. S. Kamimura, Allegra Conti, Benoit Larrat, Nicolas Tsapis, Anthony Novell   +6 more
doaj   +1 more source

Exploring the Brainpeps database [PDF]

, 2012
Since the discovery that peptides can cross the blood-brain barrier (BBB), doors have been opened to new therapeutics for CNS diseases and pain management.
Bracke, Nathalie, D'Hondt, Matthias, De Spiegeleer, Bart, Stalmans, Sofie, Wynendaele, Evelien   +4 more
core   +1 more source

Multiple blood-brain barrier transport mechanisms limit bumetanide accumulation, and therapeutic potential, in the mammalian brain [PDF]

, 2017
There is accumulating evidence that bumetanide, which has been used over decades as a potent loop diuretic, also exerts effects on brain disorders, including autism, neonatal seizures, and epilepsy, which are not related to its effects on the kidney but ...
Erker, Thomas, Fedrowitz, Maren, Hampel, Philip, Kaczmarek, Edith, Löscher, Wolfgang, Römermann, Kerstin, Sweet, Douglas H., Töllner, Kathrin   +7 more
core   +2 more sources

Adaptaquin is selectively toxic to glioma stem cells through disruption of iron and cholesterol metabolism

Molecular Oncology, EarlyView.
Adaptaquin selectively kills glioma stem cells while sparing differentiated brain cells. Transcriptomic and proteomic analyses show Adaptaquin disrupts iron and cholesterol homeostasis, with iron chelation amplifying cytotoxicity via cholesterol depletion, mitochondrial dysfunction, and elevated reactive oxygen species.
Adrien M. Vaquié, Davod R. Shah, Eliane E. S. Brechbühl, Michael McNicholas, Zhaoyang Xu, John H. Stockley, Laura Morcom, Diana Gold Diaz, Gemma C. Girdler, Rachel V. Seear, Gabriel Balmus, Rajiv R. Ratan, Harry Bulstrode, James A. Nathan, Manav Pathania, Kevin M. Brindle, David H. Rowitch   +16 more
wiley   +1 more source

Enhancing Oral Delivery of Biologics: A Non-Competitive and Cross-Reactive Anti-Leptin Receptor Nanofitin Demonstrates a Gut-Crossing Capacity in an Ex Vivo Porcine Intestinal Model

Pharmaceutics
Biotherapeutics exhibit high efficacy in targeted therapy, but their oral delivery is impeded by the harsh conditions of the gastrointestinal (GI) tract and limited intestinal absorption.
Solene Masloh, Anne Chevrel, Maxime Culot, Anaëlle Perrocheau, Yogeshvar N. Kalia, Samuel Frehel, Rémi Gaussin, Fabien Gosselet, Simon Huet, Magali Zeisser Labouebe, Leonardo Scapozza   +10 more
doaj   +1 more source

Elimination of substances from the brain parenchyma: efflux via perivascular pathways and via the blood–brain barrier

Fluids and Barriers of the CNS, 2018
This review considers efflux of substances from brain parenchyma quantified as values of clearances (CL, stated in µL g−1 min−1). Total clearance of a substance is the sum of clearance values for all available routes including perivascular pathways and ...
Stephen B. Hladky, Margery A. Barrand
doaj   +1 more source

Wnt/beta-catenin signaling controls development of the blood–brain barrier [PDF]

, 2009
The blood–brain barrier (BBB) is confined to the endothelium of brain capillaries and is indispensable for fluid homeostasis and neuronal function. In this study, we show that endothelial Wnt/beta-catenin (beta-cat) signaling regulates induction and ...
Babbage, Jane, Bangsow, Thorsten, Corada, Monica, Czupalla, Cathrin Jacqueline, Dejana, Elisabetta, Felici, Angelina, Fruttiger, Marcus, Gerhardt, Holger, Liebner, Stefan, Melchner, Harald von (Prof. Dr.), Plate, Karl H., Reis, Marco, Taddei, Andrea, Taketo, Makoto Mark, Wolburg, Hartwig   +14 more
core